Anti-Infection Drugs Market Analysis, Performance and Revenue Growth

The Business Research Company’s Anti-Infective Drugs ****** market report, covers the year-on-year growth of the ****** Anti-Infective Drugs market historic and forecast growth. It also includes chapters on the Anti-Infective Drugs market trends, geographical analysis, and competitive landscape.

Order the report at:

https://www.thebusinessresearchcompany.com/report/anti-infective-drugs-******-market-report

The ****** anti-infective drugs market size is expected to reach $130 billion by 2022, significantly growing at a CAGR of around 3% during the forecast period.

Anti-Infective Drugs Market Trends:

The anti-infective drugs market consists of sales of anti-infective drugs and related services by entities (organizations, sole traders and partnerships) that produce anti-infective drugs to treat microbial infections. This industry includes establishments that produce antibiotics to treat bacterial infections, anti-viral drugs to treat viral infections, anti-fungal drugs to treat fungal infections, anti- helminthic drugs to kill internal parasites and antiprotozoal agents.

Companies in this market are active with multiple strategic collaborations and agreements. Top companies in the anti-infective drug market are strategically partnering and collaborating with other companies to broaden their products and services. For instance, in May 2015, Janssen Pharmaceuticals Inc., subsidiary of Johnson & Johnson has entered into an exclusive worldwide license and collaboration arrangement with Achillion Pharmaceuticals Inc. to develop and commercialize one or more of Achillion`s lead hepatitis C virus (HCV) assets which include ACH-3102, ACH-3422 and sovaprevir . Also in December 2017, Evotec AG was in a strategic alliance with Forge Therapeutics Inc. to advance its novel Gram-negative antibiotic programme targeting `LpxC` for the treatment of bacterial infections. Chimerix and ContraVir Pharmaceuticals also entered into a strategic collaboration for antiviral drug candidate CMX157

The ****** Anti-Infective Drugs market is primarily driven by growing infectious diseases caused by bacteria, viruses, fungi and the expected increase in ****** healthcare expenditure.

Download a sample of the report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2138&type=smp

The ****** Anti-Infective Drugs market report covers the following regions under the geographical analysis section: Asia Pacific, Western Europe, North America, Middle East, Africa, South America, and Eastern Europe. Major countries under each of these regions are also covered under the country analysis chapters.

With prevalence of diseases such as HIV/AIDS, hepatitis, Ebola, flu caused by viral infections and increased ****** healthcare expenditure, the ****** Anti-Infective Drugs market is expected to increase in potential and scope. TBRC’s report also covers the Anti-Infective Drugs drivers and restraints in the market.

The ****** Anti-Infective Drugs market’s segment shares in each geographic region are mentioned in the report, along with the historic and forecast growth rates for each segment presented visually with supporting reasons to justify the growth rates.

The top companies included in the ****** Anti-Infective Drugs market report are Gilead, Merck & Co, GlaxosmithKline, Bristol-Myers Squibb Company, and Johnson & Johnson.

About The Business Research Company:

The Business Research Company is a Business Intelligence Company which excels in company, market and consumer research. It has offices in the UK, the US and India and a network of trained researchers in 15 countries globally.

Contact Information:

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Email: info@tbrc.info

Follow us on LinkedIn: https://in.linkedin.com/company/the-business-research-company

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.